PURPOSE: (R,S)-N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-3-piperidinyl)methoxy)-4-quinazolinamine (PAQ) is a tyrosine kinase inhibitor with high affinity for the vascular endothelial growth factor receptor 2 (VEGFR-2), which plays an important role in tumour angiogenesis. The aim of this work was to develop and evaluate in mice the (11)C-labelled analogue as an in vivo tracer for VEGFR-2 expression in solid tumours. METHODS: [(11)C]PAQ was synthesized by an N-methylation of desmethyl-PAQ using [(11)C]methyl iodide. The tracer's pharmacokinetic properties and its distribution in both subcutaneous and intraperitoneal tumour models were evaluated with positron emission tomography (PET). [(18)F]FDG was used as a reference tracer for tumour growth. PET results were corroborated by ex vivo and in vitro phosphor imaging and immunohistochemical analyses. RESULTS: In vitro assays and PET in healthy animals revealed low tracer metabolism, limited excretion over 60 min and a saturable and irreversible binding. Radiotracer uptake in subcutaneous tumour masses was low, while focal areas of high uptake (up to 8% ID/g) were observed in regions connecting the tumour to the host. Uptake was similarly high but more distributed in tumours growing within the peritoneum. The pattern of radiotracer uptake was generally different from that of the metabolic tracer [(18)F]FDG and correlated well with variations in VEGFR-2 expression determined ex vivo by immunohistochemical analysis. CONCLUSION: These results suggest that [(11)C]PAQ has potential as a noninvasive PET tracer for in vivo imaging of VEGFR-2 expression in angiogenic "hot spots".
PURPOSE: (R,S)-N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-3-piperidinyl)methoxy)-4-quinazolinamine (PAQ) is a tyrosine kinase inhibitor with high affinity for the vascular endothelial growth factor receptor 2 (VEGFR-2), which plays an important role in tumour angiogenesis. The aim of this work was to develop and evaluate in mice the (11)C-labelled analogue as an in vivo tracer for VEGFR-2 expression in solid tumours. METHODS: [(11)C]PAQ was synthesized by an N-methylation of desmethyl-PAQ using [(11)C]methyl iodide. The tracer's pharmacokinetic properties and its distribution in both subcutaneous and intraperitoneal tumour models were evaluated with positron emission tomography (PET). [(18)F]FDG was used as a reference tracer for tumour growth. PET results were corroborated by ex vivo and in vitro phosphor imaging and immunohistochemical analyses. RESULTS: In vitro assays and PET in healthy animals revealed low tracer metabolism, limited excretion over 60 min and a saturable and irreversible binding. Radiotracer uptake in subcutaneous tumour masses was low, while focal areas of high uptake (up to 8% ID/g) were observed in regions connecting the tumour to the host. Uptake was similarly high but more distributed in tumours growing within the peritoneum. The pattern of radiotracer uptake was generally different from that of the metabolic tracer [(18)F]FDG and correlated well with variations in VEGFR-2 expression determined ex vivo by immunohistochemical analysis. CONCLUSION: These results suggest that [(11)C]PAQ has potential as a noninvasive PET tracer for in vivo imaging of VEGFR-2 expression in angiogenic "hot spots".
Authors: D Fukumura; R Xavier; T Sugiura; Y Chen; E C Park; N Lu; M Selig; G Nielsen; T Taksir; R K Jain; B Seed Journal: Cell Date: 1998-09-18 Impact factor: 41.582
Authors: Roy S Herbst; John V Heymach; Michael S O'Reilly; Amir Onn; Anderson J Ryan Journal: Expert Opin Investig Drugs Date: 2007-02 Impact factor: 6.206
Authors: Daniel L Gustafson; Erica L Bradshaw-Pierce; Andrea L Merz; Joseph A Zirrolli Journal: J Pharmacol Exp Ther Date: 2006-04-27 Impact factor: 4.030
Authors: Jaya Prabhakaran; Victoria Arango; Vattoly J Majo; Norman R Simpson; Suham A Kassir; Mark D Underwood; Hanish Polavarapu; Jeffrey N Bruce; Peter Canoll; J John Mann; J S Dileep Kumar Journal: Bioorg Med Chem Lett Date: 2012-06-07 Impact factor: 2.823
Authors: Qing Cheng; Li Lu; Jonas Grafström; Maria Hägg Olofsson; Jan-Olov Thorell; Erik Samén; Katarina Johansson; Hanna-Stina Ahlzén; Sharon Stone-Elander; Stig Linder; Elias S J Arnér Journal: PLoS One Date: 2012-08-01 Impact factor: 3.240
Authors: Erik Samén; Li Lu; Jan Mulder; Jan-Olov Thorell; Peter Damberg; Tetyana Tegnebratt; Lars Holmgren; Helene Rundqvist; Sharon Stone-Elander Journal: EJNMMI Res Date: 2014-03-26 Impact factor: 3.138